Get the Stockscreener App
8.29
0.96%
-0.08
After Hours:
8.44
0.15
+1.81%
Biocryst Pharmaceuticals Inc stock is traded at $8.29, with a volume of 4.15M.
It is down -0.96% in the last 24 hours and down -7.99% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$8.37
Open:
$8.35
24h Volume:
4.15M
Relative Volume:
0.77
Market Cap:
$2.11B
Revenue:
$874.84M
Net Income/Loss:
$263.86M
P/E Ratio:
6.8905
EPS:
1.2031
Net Cash Flow:
$327.41M
1W Performance:
-8.09%
1M Performance:
-7.99%
6M Performance:
+18.94%
1Y Performance:
-20.21%
1-Day Range:
$8.215
$8.54
1-Week Range:
$8.215
$9.07
52-Week Range:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.29 | 2.13B | 874.84M | 263.86M | 327.41M | 1.2031 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Resumed | Evercore ISI | Outperform |
| Oct-15-25 | Resumed | TD Cowen | Buy |
| Oct-01-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-25 | Initiated | Wedbush | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth from pediatric expansion - Investing.com Nigeria
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings - Sahm
BCRX Should I Buy - Intellectia AI
Insider Selling: Amy Mckee Sells 11,180 Shares of BioCryst Pharm - GuruFocus
BioCryst director Amy McKee sells $100,284 in company shares - Investing.com UK
BioCryst director Amy McKee sells $100,284 in company shares By Investing.com - Investing.com South Africa
Director at Biocryst (NASDAQ: BCRX) sells 11,180 shares at $8.97 - Stock Titan
Biocryst’s BCX-17725 as new approach for Netherton syndrome - BioWorld News
Netherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight - Yahoo Finance
BCRX (NASDAQ) Form 144: Affiliate plans resale of 11,180 shares - Stock Titan
BioCryst’s SWOT analysis: rare disease stock eyes growth path By Investing.com - Investing.com Nigeria
BioCryst’s SWOT analysis: rare disease stock eyes growth path - Investing.com
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth beyond single product - Investing.com
BioCryst Pharmaceuticals’ SWOT analysis: stock gains ground on pediatric approval - Investing.com Nigeria
BioCryst Pharmaceuticals’ SWOT analysis: stock aims for profitability - Investing.com UK
BioCryst Pharmaceuticals’ SWOT analysis: stock aims for profitability By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth path By Investing.com - Investing.com Australia
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth path - Investing.com
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
Responsive Playbooks and the BCRX Inflection - Stock Traders Daily
European Navenibart Deal And Reaffirmed 2026 Outlook Could Be A Game Changer For BioCryst (BCRX) - Sahm
BioCryst Pharmaceuticals, Inc. $BCRX Shares Bought by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Biocryst (BCRX) CLO sells 62,500 shares in pre-set 10b5-1 trade - Stock Titan
BioCryst’s Navenibart Deal And Pediatric Data Shape HAE Investment Case - Sahm
BioCryst Pharmaceuticals stock (US09058V1035): Shares surge 9% after earnings - AD HOC NEWS
BCRX Jumps As Price Target Hike Caps Busy Catalyst Week - StocksToTrade
62,500-share resale registered by BCRX insider (NASDAQ: BCRX) - Stock Titan
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026 - The Manila Times
BioCryst Pharmaceuticals to Present New Research on Pediatric Hereditary Angioedema at ISPOR 2026 Conference - Quiver Quantitative
BioCryst to Present New Real-World Evidence Underscoring - GlobeNewswire
Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition - PR Newswire
Study: Kids with rare swelling disorder log 3x outpatient visits vs peers - Stock Titan
BioCryst Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
BioCryst Q1 2026 slides: dual HAE strategy targets $1.8B revenue - Investing.com Canada
Earnings call transcript: BioCryst Pharmaceuticals Q1 2026 misses EPS, revenue up - Investing.com Nigeria
Earnings call transcript: BioCryst Pharmaceuticals Q1 2026 misses EPS, revenue up By Investing.com - Investing.com South Africa
BioCryst (BCRX) Is Down 6.7% After Q1 Loss And Navenibart Deal News Has The Bull Case Changed? - Yahoo Finance
State Street (NASDAQ: BCRX) holds 4.9% of BioCryst, 12.2M shares - Stock Titan
Influenza Therapeutics Market to Reach USD 12.94 Billion by 2033 - openPR.com
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Q1 Results And Navenibart Licensing Deal - Yahoo Finance
European patients gain future access to HAE drug navenibart in $300M deal - Angioedema News
Is BioCryst Pharmaceuticals (BCRX) Pricing Reflect Its Pipeline Progress And Recent Share Performance Changes - Sahm
Number of shareholders of BioCryst Pharmaceuticals, Inc. – FWB:BO1 - TradingView
These analysts revise their forecasts on BioCryst Pharma after Q1 earnings - MSN
BioCryst Pharmaceuticals (NASDAQ:BCRX) Rating Lowered to Hold at Wall Street Zen - MarketBeat
H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
BioCryst (BCRX) Q1 2026 Earnings Transcript - AOL.com
BCRX Adjusts FY26 Revenue Outlook with Key Estimates - GuruFocus
BioCryst (BCRX) Reports Q1 Revenue Growth Amid Significant Loss - GuruFocus
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):